Ghost Tree Capital’s Coherus Oncology CHRS Stock Holding History

Ghost Tree Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-150,000	Closed	-$2.43M	–	46
2020 Q1	$2.43M	Sell	150,000 -280,000	-65%	-$5.17M	0.65%	33
2019 Q4	$7.74M	Buy	+430,000	New	+$7.93M	1.47%	25
2019 Q3	–	Sell	-175,000	Closed	-$3.87M	–	48
2019 Q2	$3.87M	Sell	175,000 -275,000	-61%	-$4.78M	0.8%	32
2019 Q1	$6.14M	Buy	+450,000	New	+$6M	1.6%	26

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ghost Tree Capital's CHRS Position: Q2 2020 in Review

Ghost Tree Capital sold out of Coherus Oncology (CHRS) in Q2 2020, closing a stake of 150,000 shares — an estimated $2.43M sold.

Ghost Tree Capital first reported a position in CHRS in Q1 2019 and held it in 4 quarters. The position peaked at $7.74M in Q4 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2020.

Ghost Tree Capital reported no remaining Coherus Oncology position as of Q2 2020 after selling out during the quarter.
Ghost Tree Capital sold 150,000 Coherus Oncology shares in Q2 2020, an estimated $2.43M.
Ghost Tree Capital first reported a position in Coherus Oncology in Q1 2019 and held it in 4 quarters.
Ghost Tree Capital's Coherus Oncology position peaked at $7.74M in Q4 2019.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2020.

Based on Ghost Tree Capital's 13F filing for Q2 2020, filed 14 Aug 2020.